Multicenter Evaluation of Octreotide as Secondary Prophylaxis in Patients With Left Ventricular Assist Devices and Gastrointestinal Bleeding
Authors:
- Keyur B. ShahKSKeyur B. Shah
- Sampath GundaSGSampath Gunda
- Sitaramesh EmaniSESitaramesh Emani
- Manreet K. KanwarMKManreet K. Kanwar
- Nir UrielNUNir Uriel
- Paolo C. ColomboPCPaolo C. Colombo
- Patricia A. UberPUPatricia A. Uber
- Melissa L. SearsMSMelissa L. Sears
- Joyce ChuangJCJoyce Chuang
- David J. FarrarDFDavid J. Farrar
- Donald F. BrophyDBDonald F. Brophy
- George B. SmallfieldGSGeorge B. Smallfield
Open Access
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 10 (11) , e004500
Abstract
Background: Gastrointestinal (GI) bleeding is one of the most common complications after continuous-flow left ventricular assist device implantation. More than one third of patients with incident bleed go on to develop recurrent GI bleeding. Octreotide, a somatostatin analog, is proposed to reduce the risk of recurrent GI bleeding in this population. Methods and Results: This multicenter, retrospective analysis evaluated 51 continuous-flow left ventricular assist device patients who received secondary prophylaxis with octreotide after their index GI bleed from 2009 to 2015. All patients had a hospitalization for GI bleed and received octreotide after discharge. Patient demographics, medical and medication history, and clinical characteristics of patients who rebled after receiving octreotide were compared with non–rebleeders. These data were also compared with matched historical control patients previously enrolled in the HMII (HeartMate II) clinical trials, none of whom received octreotide, to provide a context for the bleeding rates. Twelve patients (24%) who received secondary octreotide prophylaxis developed another GI bleed, whereas 39 (76%) did not. There were similar intergroup demographics; however, significantly more bleeders had a previous GI bleeding history before left ventricular assist device placement (33% versus 5%; P =0.02) and greater frequency of angiodysplasia confirmed during endoscopy (58% versus 23%; P =0.03). Fewer patients in this study experienced a recurrent GI bleed compared with a matched historical control group that did not receive octreotide (24% versus 43%; P =0.04). Conclusions: Patients with continuous-flow left ventricular assist device receiving secondary prophylaxis with octreotide had a significantly lower GI bleed recurrence compared with historical controls not treated with octreotide. Additional prospective studies are needed to confirm these data.Keywords
This publication has 25 references indexed in Scilit:
- Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device SupportJACC, 2014
- Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and managementAlimentary Pharmacology & Therapeutics, 2013
- Octreotide for Left Ventricular Assist Device–Related Gastrointestinal HemorrhageASAIO Journal, 2013
- Gastrointestinal bleeding with the HeartMate II left ventricular assist deviceThe Journal of Heart and Lung Transplantation, 2012
- Incidence and Management of Gastrointestinal Bleeding With Continuous Flow Assist DevicesThe Annals of Thoracic Surgery, 2012
- Acquired von Willebrand Syndrome After Continuous-Flow Mechanical Device Support Contributes to a High Prevalence of Bleeding During Long-Term Support and at the Time of TransplantationJACC, 2010
- Somatostatin Analogues in the Treatment of Recurrent Bleeding from Gastrointestinal Vascular Malformations: An Overview and Systematic Review of Prospective Observational StudiesDigestive Diseases and Sciences, 2010
- Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist deviceEuropean Journal of Cardio-Thoracic Surgery, 2009
- Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devicesThe Journal of Thoracic and Cardiovascular Surgery, 2009
- The Biological Basis of Thrombosis and Bleeding in Patients with Ventricular Assist DevicesJournal of Cardiovascular Translational Research, 2008